Dideoxynucleosides are less inhibitory in vitro against human immunodeficiency virus type 2 (HIV-2) than against HIV-1.
The antiviral activities of various dideoxynucleosides against LAV strains of human immunodeficiency viruses type 1 (HIV-1) and type 2 (HIV-2) were evaluated. Significantly more 3'-azido-3'-deoxythymidine was required to inhibit the replication of HIV-2 than HIV-1 in three human cell lines. HIV-2 also appeared more resistant than HIV-1 to other dideoxynucleosides. These results suggest that dideoxynucleosides may be less effective in vivo for HIV-2 infection and that a broader range of clinical isolates of human retroviruses should be examined for drug susceptibility in vitro.
D000998:Antiviral Agents / Q000494:pharmacology*; D002460:Cell Line; D004352:Drug Resistance, Microbial; D006678:HIV / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D013601:T-Lymphocytes / Q000187:drug effects; D013936:Thymidine / Q000031:analogs & derivatives* / Q000494:pharmacology; D014779:Virus Replication / Q000187:drug effects*; D015215:Zidovudine
D000998:Antiviral Agents; D015215:Zidovudine; D013936:Thymidine